Status:
COMPLETED
Combined Haploidentical-Cord Blood Transplantation for Adults and Children
Lead Sponsor:
University of Chicago
Conditions:
Leukemia
Myelodysplastic Syndrome
Eligibility:
All Genders
1+ years
Phase:
NA
Brief Summary
The primary objective is to assess the rate of engraftment with combined haploidentical-cord blood transplantation. The secondary objective is to evaluate the incidence and severity of acute and chron...
Eligibility Criteria
Inclusion
- Patients will be eligible for this study if they have any one of the diseases that are known to be cured after allogeneic stem cell transplantation.
- Relapsed or refractory acute leukemia (myeloid or lymphoid)
- Acute leukemia in first remission at high-risk for recurrence
- Chronic myelogenous leukemia in accelerated phase or blast-crisis
- Chronic myelogenous leukemia in chronic phase
- Recurrent or refractory malignant lymphoma or Hodgkin lymphoma
- Chronic lymphocytic leukemia, relapsed or with poor prognostic features
- Multiple myeloma
- Myelodysplastic syndrome
- Chronic myeloproliferative disease
- Hemoglobinopathies
- Aplastic anemia
Exclusion
- Zubrod performance status \> 2
- Life expectancy is severely limited by concomitant illness
- Patients with severely decreased LVEF or impaired pulmonary function tests(PFT's)
- Estimated Creatinine Clearance \<50 ml/min
- Serum bilirubin\> 2.0 mg/dl or SGPT \>3 x upper limit of normal
- Evidence of chronic active hepatitis or cirrhosis
- HIV-positive
- Patient is pregnant
- Patient or guardian not able to sign informed consent
Key Trial Info
Start Date :
October 9 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2018
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT00943800
Start Date
October 9 2006
End Date
September 1 2018
Last Update
January 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Chicago
Chicago, Illinois, United States, 60637